Vancouver, Canada

Dunja Urosev

USPTO Granted Patents = 11 

 

 

Average Co-Inventor Count = 6.1

ph-index = 3

Forward Citations = 36(Granted Patents)


Company Filing History:


Years Active: 2018-2025

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Dunja Urosev: Innovator in Antibody-Drug Conjugates

Introduction

Dunja Urosev is a prominent inventor based in Vancouver, Canada. She has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates. With a total of 11 patents to her name, her work focuses on innovative therapeutic solutions for cancer treatment.

Latest Patents

Among her latest patents is the invention of antibody-drug conjugates targeting folate receptor alpha. This invention involves ADCs that comprise an antibody construct specifically designed to bind to human folate receptor alpha. These ADCs are particularly useful as therapeutics in cancer treatment. Another notable patent is for engineered immunoglobulin heavy chain-light chain pairs. This invention provides heterodimer pairs that can enhance the preferential pairing of heavy and light chains, improving the efficacy of immunoglobulin-based therapies.

Career Highlights

Dunja has worked with notable companies such as Zymeworks Inc. and Zymeworks BC Inc. Her experience in these organizations has allowed her to advance her research and contribute to groundbreaking innovations in the field of immunotherapy.

Collaborations

Dunja has collaborated with several professionals in her field, including Stacey A L Tom-Yew and Mario Sanches. These collaborations have further enriched her research and development efforts.

Conclusion

Dunja Urosev is a leading inventor whose work in antibody-drug conjugates has the potential to transform cancer treatment. Her innovative patents and collaborations highlight her commitment to advancing biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…